{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:27:04Z","timestamp":1786768024271,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.msard.2021.103189","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T11:54:47Z","timestamp":1627905287000},"page":"103189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases"],"prefix":"10.1016","volume":"55","author":[{"given":"Itay","family":"Lotan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Romanow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103189_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102917","article-title":"COVID-19 and emerging spinal cord complications: A systematic review","volume":"51","author":"Mondal","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103189_bib0001","series-title":"COVID-19 mRNA Vaccines (Pfizer-BioNTech and Moderna) and MS","year":"2021"},{"key":"10.1016\/j.msard.2021.103189_bib0002","series-title":"COVID-19 Vaccination Guidance for People with MS","year":"2021"},{"key":"10.1016\/j.msard.2021.103189_bib0003","series-title":"COVID-19 Vaccine Guidance for People Living with MS","year":"2021"},{"key":"10.1016\/j.msard.2021.103189_bib0004","series-title":"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the USA","year":"2021"},{"key":"10.1016\/j.msard.2021.103189_bib0005","series-title":"MS, the Coronavirus and Vaccines\u2013Updated Global Advice","year":"2021"},{"issue":"13","key":"10.1016\/j.msard.2021.103189_bib0006","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1177\/0961203309345730","article-title":"Transverse myelitis and vaccines\u2013A multi-analysis","volume":"18","author":"Agmon-Levin","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.msard.2021.103189_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102886","article-title":"COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America\u2013COVID-19 in MS and NMOSD patients in LATAM","volume":"51","author":"Alonso","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"17","key":"10.1016\/j.msard.2021.103189_bib0008","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1111\/febs.15375","article-title":"A guide to COVID-19\u2013A global pandemic caused by the novel coronavirus SARS-CoV-2","volume":"287","author":"Atzrodt","year":"2020","journal-title":"FEBS J."},{"issue":"8","key":"10.1016\/j.msard.2021.103189_bib0009","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jnnp-2016-314839","article-title":"Incidence and prevalence of NMOSD in Australia and New Zealand","volume":"88","author":"Bukhari","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2021.103189_bib0010","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed."},{"issue":"3","key":"10.1016\/j.msard.2021.103189_bib0011","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000991","article-title":"Vaccine hesitancy in patients with multiple sclerosis\u2013Preparing for the SARS-CoV-2 vaccination challenge","volume":"8","author":"Diem","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103189_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102788","article-title":"Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the USA","volume":"49","author":"Ehde","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2021.103189_bib0013","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000787","article-title":"Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders","volume":"7","author":"Fan","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.msard.2021.103189_bib0014","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00415-011-5984-2","article-title":"Immunizations and risk of multiple sclerosis\u2013Systematic review and meta-analysis","volume":"258","author":"Farez","year":"2011","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2021.103189_bib0015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2021.103189_bib0016","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/587063","article-title":"Vaccination in patients with chronic rheumatic or autoimmune diseases","volume":"46","author":"Gl\u00fcck","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.msard.2021.103189_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium\u2013Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."},{"issue":"2","key":"10.1016\/j.msard.2021.103189_bib0018","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"issue":"12","key":"10.1016\/j.msard.2021.103189_bib0019","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.jocn.2008.05.002","article-title":"Post-vaccination encephalomyelitis\u2013Literature review and illustrative case","volume":"15","author":"Huynh","year":"2008","journal-title":"J. Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.msard.2021.103189_bib0020","first-page":"e181","article-title":"Epidemiology of NMOSD in Sweden from 1987 to 2013\u2013A nationwide population-based study","volume":"93","author":"Jonsson","year":"2019","journal-title":"Neurol."},{"issue":"3","key":"10.1016\/j.msard.2021.103189_bib0021","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2013.10.003","article-title":"The spectrum of post-vaccination inflammatory CNS demyelinating syndromes","volume":"13","author":"Karussis","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2021.103189_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198114","article-title":"COVID-19 vaccine\u2013A comprehensive status report","volume":"288","author":"Kaur","year":"2020","journal-title":"Virus Res."},{"issue":"3","key":"10.1016\/j.msard.2021.103189_bib0023","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/21645515.2020.1804777","article-title":"SARS-CoV-2 vaccine candidates in rapid development","volume":"17","author":"Li","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"issue":"3","key":"10.1016\/j.msard.2021.103189_bib0024","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11481-020-09944-5","article-title":"The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections","volume":"15","author":"Machhi","year":"2020","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"6","key":"10.1016\/j.msard.2021.103189_bib0025","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00415-016-8263-4","article-title":"Vaccines and multiple sclerosis\u2013A systematic review","volume":"264","author":"Mailand","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103189_bib0026","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msard.2018.05.003","article-title":"Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder","volume":"23","author":"Mealy","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2021.103189_bib0027","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the USA\u2013A multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2021.103189_bib0028","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/jnnp-2017-317321","article-title":"Nationwide epidemiological study of neuromyelitis optica in Japan","volume":"89","author":"Miyamoto","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2021.103189_bib0029","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-981-13-3681-2_2","article-title":"The immune system and its dysregulation with aging","volume":"91","author":"M\u00fcller","year":"2019","journal-title":"Subcell. Biochem."},{"issue":"2","key":"10.1016\/j.msard.2021.103189_bib0030","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.vaccine.2018.11.045","article-title":"Causal relationship between immunological responses and adverse reactions following vaccination","volume":"37","author":"Nakayama","year":"2019","journal-title":"Vaccine"},{"issue":"27","key":"10.1016\/j.msard.2021.103189_bib0031","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10262","key":"10.1016\/j.msard.2021.103189_bib0033","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(20)32137-1","article-title":"SARS-CoV-2 immunity\u2013Review and applications to phase 3 vaccine candidates","volume":"396","author":"Poland","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.103189_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173751","article-title":"COVID-19 vaccine\u2013A recent update in pipeline vaccines, their design and development strategies","volume":"892","author":"Rawat","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.msard.2021.103189_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001035","article-title":"Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases\u2013A systematic literature review for the 2019 update of EULAR recommendations","volume":"5","author":"Rondaan","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.msard.2021.103189_bib0036","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jim.2018.08.005","article-title":"Aging and the immune system\u2013An overview","volume":"463","author":"Sadighi Akha","year":"2018","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.msard.2021.103189_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/ene.14952","article-title":"Systematic review of cases of acute myelitis in individuals with COVID-19","author":"Schulte","year":"2021","journal-title":"Eur. J. Neurol"},{"issue":"4","key":"10.1016\/j.msard.2021.103189_bib0037","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000149390","volume":"20","author":"Siddell","year":"1983","journal-title":"Coronaviridae. Intervirology"},{"issue":"15\u201316","key":"10.1016\/j.msard.2021.103189_bib0038","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/S0264-410X(98)00467-8","article-title":"Reactogenicity in the elderly of nine commercial influenza vaccines\u2013Results from the Italian SVEVA study. Study for the evaluation of adverse events of influenza vaccination","volume":"17","author":"Spila-Alegiani","year":"1999","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.msard.2021.103189_bib0039","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taw012","article-title":"Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travelers\u2013Questionnaire survey in Japan over a 1 year period","volume":"23","author":"Tanizaki","year":"2016","journal-title":"J. Travel Med."},{"issue":"8","key":"10.1016\/j.msard.2021.103189_bib0040","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19)\u2013A review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.msard.2021.103189_bib0041","article-title":"COVID-19 vaccination willingness among people with multiple sclerosis","volume":"7","author":"Xiang","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"6","key":"10.1016\/j.msard.2021.103189_bib0042","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1046\/j.1468-1331.2002.00447_9.x","article-title":"Transverse myelitis after vaccination","volume":"9","author":"Zanoni","year":"2002","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.103189_bib0043","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/22221751.2021.1891002","article-title":"Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response","volume":"10","author":"Zhuang","year":"2021","journal-title":"Emerg. Microbes Infect."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821004569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821004569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T03:37:58Z","timestamp":1786765078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821004569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":44,"alternative-id":["S2211034821004569"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103189","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103189"}}